Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

New Providence, Rhode Island Clinical Trials

A listing of New Providence, Rhode Island clinical trials actively recruiting patient volunteers.

RESULTS

Found (40) clinical trials

BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial

A standard treatment for your cancer is called FOLFIRINOX (this utilizes the FDA approved chemotherapy drugs fluorouracil, leucovorin, oxaliplatin and irinotecan). In this study you will receive the chemotherapy treatment FOLFOX-A (fluorouracil, oxaliplatin, leucovorin and Abraxane ) which substitutes irinotecan for the FDA approved chemotherapy drug Abraxane . Even though ...

Phase

1.81 miles

Learn More »

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

This is a Phase 1b/2, open-label, multi-center, multiple-dose, safety, clinical activity, PK, and PD study of avelumab in combination with other immune modulators in adult patients with locally advanced or metastatic solid tumors (eg, non-small cell lung cancer (NSCLC), melanoma, squamous cell carcinoma of the head and neck (SCCHN), triple-negative ...

Phase

1.88 miles

Learn More »

Gut Microbiota Changes After Fecal Microbiota Transplantation

The exact mechanism by which FMT is effective is presently unknown. A recent study of 14 patients with recurrent CDI treated with FMT35 showed decreased diversity pre-FMT with gut microbiota becoming more diverse and similar to donors post-FMT. This group showed significant changes in 3 taxonomic orders but no single ...

Phase

1.88 miles

Learn More »

Early ART to Limit Infection and Establishment of Reservoir

The study is being done to: start ART early in those recently or acutely infected with HIV-1 see how starting ART as soon as the infection is found affects the amount of HIV-1 in blood and how well the body fights the HIV-1 infection look at the amount of HIV-1 ...

Phase

1.88 miles

Learn More »

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors Lymphomas or Multiple Myeloma (The MATCH Screening Trial)

PRIMARY OBJECTIVE: I. To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma. SECONDARY OBJECTIVES: I. To evaluate the proportion of patients alive and progression free at 6 months of treatment with targeted study agent in patients with advanced ...

Phase

1.88 miles

Learn More »

BrUOG 324: Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial

Effective adjuvant treatment can increase cure in patients with high-risk resected melanoma. High dose interferon is a standard of care in the adjuvant setting but is highly toxic and marginally effective. The combination of ipilimumab and nivolumab is the most active regimen in patients with advanced melanoma so there is ...

Phase

1.88 miles

Learn More »

A Study of Semorinemab in Patients With Moderate Alzheimer's Disease

This Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the clinical efficacy, safety, pharmacokinetics, and pharmacodynamics of semorinemab in patients with moderate AD. The study consists of a screening period, a double-blind treatment period, an optional open-label extension (OLE) period, and a safety follow-up period.

Phase

1.88 miles

Learn More »

Efficacy and Safety of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU)

The purpose this study is to evaluate the efficacy, safety, and pharmacokinetics of GDC-0853 compared with placebo in participants with Chronic Spontaneous Urticaria (CSU) refractory to anti-histamines.

Phase

2.69 miles

Learn More »

Pulmonary Hypertension and Anastrozole Trial

The primary objectives of this study are to determine whether the study drug, anastrozole may improve six minute walk distance at six months compared to placebo and to assess safety and side effects up to twelve months in pulmonary arterial hypertension (PAH).

Phase

2.69 miles

Learn More »